Rare Tumor Mimics Synovial Sarcoma: Why Accurate Diagnosis Matters

A recent case report highlights a rare GLI1-altered mesenchymal tumor presenting in the pleura (lining of the lung), a location where tumors can closely resemble synovial sarcoma.

This case underscores a critical challenge in rare cancers — different tumors can appear similar under imaging and even under the microscope, making accurate diagnosis essential for appropriate treatment.

A Rare and Complex Case

A 39-year-old woman was found to have an incidental mass in the chest during routine imaging. Further scans identified a pleural-based tumor near the lung and spine.

The patient underwent:

• Advanced imaging (CT and MRI)
• Surgical resection of the tumor

Initial findings suggested a biphasic tumor — meaning it had both epithelial and spindle cell features — a pattern often seen in synovial sarcoma.

When Tumors Look Alike

Because of its structure and location, synovial sarcoma was considered as a possible diagnosis.

However, further testing revealed:

• Absence of SS18 gene rearrangement (a defining feature of synovial sarcoma)
• Strong GLI1 protein expression
• Confirmation of an ACTB-GLI1 gene fusion through next-generation sequencing

These findings led to a final diagnosis of a GLI1-altered mesenchymal tumor, a rare and distinct entity.

Treatment and Outcome

The tumor was successfully removed through minimally invasive surgery. After multidisciplinary discussion, the patient chose active surveillance rather than additional therapy.

At one-year follow-up, she remained disease-free, highlighting that some rare tumors may follow a more indolent course when properly identified.

Why This Matters for Synovial Sarcoma

This case highlights several important lessons for the synovial sarcoma community:

• Not all biphasic tumors are synovial sarcoma
• Rare tumors can closely mimic synovial sarcoma in both structure and location
• Molecular testing is essential to confirm the correct diagnosis
• Accurate diagnosis helps avoid unnecessary or inappropriate treatment

The Bigger Picture

GLI1-altered tumors are a newly recognized group of rare soft tissue tumors driven by specific gene fusions. While research is ongoing, there are currently no established targeted therapies for these tumors.

For synovial sarcoma and other rare cancers, this reinforces the importance of:

• Specialized sarcoma pathology review
• Molecular and genetic testing
• Multidisciplinary care at experienced centers

As research advances, distinguishing between similar tumor types will continue to play a critical role in guiding treatment and improving outcomes.

For more detailed information, please refer to the original publication. For more information about synovial sarcoma resources and support, please visit our website.